Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RCEL
SELLAVITA Medical, Inc. · Healthcare · United States · $142M · Avg Vol: $2M/d
COMPANY DESCRIPTION
AVITA Medical, Inc. is a regenerative medicine company focused on skin repair and reconstruction, primarily known for its RECELL System. The RECELL System uses a patient's own skin to create a regenerative suspension, enabling rapid treatment of burns, scars, and other skin defects. This proprietary technology provides a significant competitive advantage in the advanced wound care and aesthetic markets, offering a unique and effective solution for complex skin injuries.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.4M | 50.1M | 64.3M | 71.6M | 27.7% | 72.3M | 83.9M | 107.7M | 22.6% |
| EPS | -1.07 | -1.40 | -2.39 | -1.74 | — | -1.57 | -1.45 | -0.85 | — |
| Shares | 25.2M | 25.7M | 26.4M | 30.6M | +21.3% | 30.8M | — | — | — |
| Debt | 0.9M | 42.4M | 46.0M | 46.0M | 268.8% | 48.1M | — | — | — |
| Equity | 84.7M | 49.1M | 4.5M | -16.6M | -77.0% | — | — | — | — |
| Op CF | -19.1M | -38.0M | -48.9M | -31.2M | — | -31.0M | — | — | — |
| Inv CF | -19.3M | 1.6M | 37.4M | 12.5M | — | — | — | — | — |
| Fin CF | 0.9M | 40.4M | 3.5M | 14.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RCEL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc.(you) | $142M | 33 | SELL |
| APYX | Apyx Medical Corporation | $165M | 36 | HOLD |
| MXCT | MaxCyte, Inc. | $116M | 28 | SELL |
| TMCI | Treace Medical Concepts, Inc. | $259M | 33 | SELL |
| QTRX | Quanterix Corporation | $173M | 20 | STRONG SELL |
| RXST | RxSight, Inc. | $215M | 22 | SELL |
| STIM | Neuronetics, Inc. | $120M | 15 | STRONG SELL |
| CVRX | CVRx, Inc. | $126M | 12 | STRONG SELL |
| OWLT | Owlet, Inc. | $153M | 11 | STRONG SELL |
| INGN | Inogen, Inc. | $167M | 55 | HOLD |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%